Melanoma Cells Secrete Factors to Promote Tumor Growth
|
By LabMedica International staff writers Posted on 12 Feb 2019 |
|
Image: Part of the Myosin II structure. Atoms in the heavy chain are colored pink (on the left-hand side); atoms in the light chains are colored faded-orange and faded-yellow (also on the left-hand side) (Photo courtesy of Wikimedia Commons).
A team of British researchers found that high Myosin II activity in invasive melanoma cells induced reprogramming of innate immune responses in the local microenvironment to support tumor growth.
Myosin II (also known as conventional myosin) is the myosin type responsible for producing contraction in muscle cells, and ROCK (Rho-associated protein kinase)-Myosin II was found to drive rounded-amoeboid migration in cancer cells during metastatic dissemination.
Following up this line of research, investigators at Queen Mary University of London (United Kingdom) reported in the January 31, 2019, online edition of the journal Cell that analysis of human melanoma biopsies revealed that amoeboid melanoma cells with high Myosin II activity were predominant in the invasive fronts of primary tumors in proximity to tumor-associated macrophages and vessels. Proteomic analysis showed that ROCK-Myosin II activity in amoeboid cancer cells controlled an immunomodulatory secretome – comprising all the factors secreted by the cell into the extracellular space - enabling the recruitment of monocytes and their differentiation into tumor-promoting macrophages. Both amoeboid cancer cells and their associated macrophages supported an abnormal system of blood vessels, which ultimately facilitated tumor progression.
Mechanistically, amoeboid cancer cells maintained their behavior via ROCK-Myosin II-driven interleukin 1 alpha (IL-1alpha) secretion and NF-kappaB (nuclear factor kappa-light-chain-enhancer of activated B cells) activation.
In addition, using an array of tumor models, the investigators demonstrated that high Myosin II activity in tumor cells reprogrammed the innate immune microenvironment to support tumor growth.
"This study highlights how cancer cells interact with and influence their surrounding environment to grow and spread. Developing treatments that target the chemicals that alter the immune system could help to prevent the spread of the disease," said senior author Dr. Victoria Sanz-Moreno, professor of cancer cell biology at Queen Mary University of London. "We are excited to find out whether inhibitor drugs could be used in combination with other targeted therapies. By identifying effective treatment combinations, we hope that in the future Myosin II and interleukin 1alpha inhibitors could be used to improve patient outcomes and reduce the risk of melanoma coming back."
Related Links:
Queen Mary University of London
Myosin II (also known as conventional myosin) is the myosin type responsible for producing contraction in muscle cells, and ROCK (Rho-associated protein kinase)-Myosin II was found to drive rounded-amoeboid migration in cancer cells during metastatic dissemination.
Following up this line of research, investigators at Queen Mary University of London (United Kingdom) reported in the January 31, 2019, online edition of the journal Cell that analysis of human melanoma biopsies revealed that amoeboid melanoma cells with high Myosin II activity were predominant in the invasive fronts of primary tumors in proximity to tumor-associated macrophages and vessels. Proteomic analysis showed that ROCK-Myosin II activity in amoeboid cancer cells controlled an immunomodulatory secretome – comprising all the factors secreted by the cell into the extracellular space - enabling the recruitment of monocytes and their differentiation into tumor-promoting macrophages. Both amoeboid cancer cells and their associated macrophages supported an abnormal system of blood vessels, which ultimately facilitated tumor progression.
Mechanistically, amoeboid cancer cells maintained their behavior via ROCK-Myosin II-driven interleukin 1 alpha (IL-1alpha) secretion and NF-kappaB (nuclear factor kappa-light-chain-enhancer of activated B cells) activation.
In addition, using an array of tumor models, the investigators demonstrated that high Myosin II activity in tumor cells reprogrammed the innate immune microenvironment to support tumor growth.
"This study highlights how cancer cells interact with and influence their surrounding environment to grow and spread. Developing treatments that target the chemicals that alter the immune system could help to prevent the spread of the disease," said senior author Dr. Victoria Sanz-Moreno, professor of cancer cell biology at Queen Mary University of London. "We are excited to find out whether inhibitor drugs could be used in combination with other targeted therapies. By identifying effective treatment combinations, we hope that in the future Myosin II and interleukin 1alpha inhibitors could be used to improve patient outcomes and reduce the risk of melanoma coming back."
Related Links:
Queen Mary University of London
Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
New
Rapid Sepsis Test
SeptiCyte RAPID
New
Chromogenic Culture System
InTray™ COLOREX™ ECC
Latest BioResearch News
- Study Links Midlife Vitamin D to Lower Tau in Alzheimer's
- International Consensus Standardizes Tumor Microbiota Detection and Reporting
- Common Metablolic Enzyme Could Predict Response to Cancer Immunotherapy
- Newly Identfied Genetic Variants in MND Support Prognosis and Family Testing
- Innate Immunity Variants Associated With Earlier Breast Cancer in BRCA1 Carriers
- Genetic Cause Identified for Severe Infant Epilepsy
- Study Reveals Diagnostic and Therapeutic Target in Rare Pancreatic Tumors
- Researchers Identify Survival Pathway Undermining Targeted Cancer Drugs
- Large-Scale Study Maps DNA Damage Signatures Across Multiple Cancers
- Study Identifies Distinct Immune Signatures to Early Depression and Psychosis
- Genetic Mutation Behind Aggressive Adult Leukemia Offers Treatment Clues
- Disease Gene Discovery Advances Diagnosis of Rare Movement Disorders
- Genetic Discovery Could Improve Diagnosis of Drug-Resistant Epilepsy
- Genetic Discovery May Improve Diagnosis of Rare Dementia Subtype
- Mass Spectrometry Technique Detects Protein and Sugar Changes in Neurodegeneration
- Barcoded DNA Sheds Light on Hidden Complexities in Breast Cancer Detection
Channels
Clinical Chemistry
view channel
Next Generation Automated Analyzers Increase Throughput for Clinical Chemistry and Electrolyte Testing
Clinical laboratories continue to face staffing shortages, limited space, and growing test volumes that pressure chemistry and electrolyte workflows. Maintaining rapid turnaround times increasingly depends... Read more
Blood Metabolite Test Detects Early Cognitive Decline
Timely identification of individuals at risk of dementia remains difficult because symptoms commonly appear only after significant neurodegeneration. Accessible screening tools that flag subtle cognitive... Read more
Molecular Diagnostics
view channel
Immune Signatures in Blood Help Inform Cancer Risk in Lynch Syndrome
Lynch syndrome is a hereditary condition that increases risk for colorectal and endometrial cancers and often results in earlier-onset disease. Clinicians need better ways to stratify asymptomatic carriers... Read more
Genetic Marker Predicts Early Heart Failure in Pulmonary Arterial Hypertension
Pulmonary arterial hypertension is a progressive condition characterized by obstructed pulmonary blood flow and strain on the right heart, with half of patients dying within five years of diagnosis.... Read more
Genomic Subtyping Assays Identify High-Risk Early-Stage Breast Cancers
Racial survival disparities in early-stage breast cancer remain a persistent clinical concern in the United States, with Black women experiencing higher mortality despite similar treatments.... Read more
cfDNA Methylation Assay Enables Multi-Disease Detection from Single Blood Sample
Early, accurate detection of cancer and organ disease remains limited by cost, reliance on targeted mutation assays, and uncertainty about the signal’s tissue of origin. Many liquid biopsy approaches require... Read moreHematology
view channel
Open Multi-Omics Platform Identifies Prognostic Subtypes in Blood Cancers
Blood cancers encompass diverse entities whose biology and clinical behavior are best understood through integrative analyses across large cohorts. However, multi‑omic datasets and outcomes information... Read more
AI-Powered Digital Workflow Standardizes Bone Marrow Aspirate Morphology
Bone marrow aspirate examination is central to diagnosing and monitoring blood cancers and other serious hematologic diseases, yet the process in many laboratories remains manual and highly dependent on... Read more
Immunology
view channel
Combined Screening Approach Identifies Early Leprosy Cases
Leprosy remains a significant public health concern, with more than 200,000 new cases reported globally each year and early disease often escaping routine laboratory detection. In its initial phase, bacterial... Read more
Antibody Blood Test Identifies Active TB and Distinguishes Latent Infection
Active tuberculosis (TB) remains a leading cause of death and illness worldwide, yet distinguishing contagious disease from latent infection continues to challenge clinicians. Standard screening tools... Read more
FDA Approval Expands Use of PD-L1 Companion Diagnostic in Esophageal and GEJ Carcinomas
Esophageal and gastroesophageal junction carcinomas (GEJ) have a poor prognosis, with approximately 16,250 deaths in the United States in 2025 and a five-year relative survival of 21.9%.... Read more
Study Identifies Inflammatory Pathway Driving Immunotherapy Resistance in Bladder Cancer
Bladder cancer remains a prevalent malignancy with variable responses to immune checkpoint inhibitors. Clinicians often observe elevated C-reactive protein and interleukin-6 in affected patients, yet the... Read moreMicrobiology
view channel
New Bacterial Target Identified for Early Detection of Noma
Noma is a rapidly progressing orofacial infection that begins as gingivitis and can destroy oral and facial tissues, primarily affecting young children living in extreme poverty. Without treatment, it... Read more
Genomic Analysis Links Emerging Streptococcal Strains to Specific Infections
Streptococcus dysgalactiae subspecies equisimilis (SDSE) infections are increasing worldwide and include variants that may lead to severe disease. Researchers now report that whole-genome sequencing of... Read more
Pathology
view channel
AI Tool Predicts Chemotherapy Response in Small Cell Lung Cancer
Small cell lung cancer often presents at an extensive stage and progresses rapidly, leaving little time to tailor first-line therapy. Clinicians currently lack biomarkers to guide which patients will benefit... Read more_image.png "Image: Through neoadjuvant therapy combining chemotherapy with immune checkpoint inhibitors (ICI) for 46 LAGC patients and single-cell transcriptome sequencing, researchers found that tumor cells in the treatment-sensitive group specifically upregulated MHC-II (tumor-specific major histocompatibility complex class II, tsMHC-II) molecules (photo courtesy of Science China Press)")
Tumor-Specific Biomarker Predicts Neoadjuvant Immunotherapy Response in Gastric Cancer
Gastric cancer is the fifth most common malignancy and the fourth leading cause of cancer mortality worldwide, with China bearing nearly half of the global burden. Only a subset of patients benefit from... Read more
Technology
view channel
New AI Tool Enables Rapid Treatment Selection in Pediatric Leukemia
Children with T-cell acute lymphoblastic leukemia face an aggressive disease that remains difficult to treat. Although remission rates have improved, many survivors experience long-term effects from intensive... Read more
Breakthrough Mass Spectrometry Design Could Enable Ultra-Low Abundance Detection
Mass spectrometry is central to identifying and quantifying molecules in complex biological samples, but conventional instruments typically analyze ions sequentially, which can limit detection of rare species.... Read more
Industry
view channel
Global Partnership Aims to Streamline NGS Tumor Profiling in Oncology Trials
CellCarta and Pillar Biosciences announced a global, multi-year strategic partnership on April 2, 2026 to broaden access to operationally streamlined next-generation sequencing (NGS) tumor profiling for... Read more
